RA Capital Management 13F holdings, Q1 2019
Holdings as of March 31, 2019 · filings on SEC EDGAR · latest filing →
RA Capital Management disclosed 29 US equity positions worth $2.3bn in its Q1 2019 13F filing. The largest position was ASND at 21.0% of the reported book, followed by WVE and SYNTHORX INC. Against the Q4 2018 filing, it opened 6 new positions, added to 3 and reduced 6 among the top 29 holdings.
What did RA Capital Management own in Q1 2019? Top 29 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q4 2018 |
|---|---|---|---|---|---|---|---|
| 1 | ASND ASCENDIS PHARMA A S | Healthcare | 21.0% | $486.4m | 4,132,442 | -3% | reduced |
| 2 | WVE WAVE LIFE SCIENCES LTD | Healthcare | 13.0% | $302.1m | 7,775,207 | 4% | added |
| 3 | SYNTHORX INC | 8.5% | $198.1m | 9,724,598 | 0% | held | |
| 4 | ZOGENIX INC | 5.7% | $131.0m | 2,382,168 | 0% | held | |
| 5 | RA PHARMACEUTICALS INC | 4.7% | $108.8m | 4,858,260 | 0% | held | |
| 6 | INFLARX NV | 4.6% | $106.2m | 2,810,708 | 35% | added | |
| 7 | ORCHARD THERAPEUTICS PLC | 3.9% | $91.3m | 5,108,330 | 5% | added | |
| 8 | EIDOS THERAPEUTICS INC | 3.9% | $91.1m | 2,162,671 | 0% | held | |
| 9 | MYOVANT SCIENCES LTD | 3.6% | $84.6m | 3,544,227 | -5% | reduced | |
| 10 | BCRX BIOCRYST PHARMACEUTICALS | Healthcare | 3.0% | $70.5m | 8,659,983 | -19% | reduced |
| 11 | TGTX TG THERAPEUTICS INC | Healthcare | 2.8% | $65.9m | 8,198,337 | 0% | held |
| 12 | SG7 SAGE THERAPEUTICS INC | 2.6% | $61.1m | 384,001 | – | new | |
| 13 | RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 2.2% | $51.7m | 1,884,782 | -3% | reduced |
| 14 | AXSM AXSOME THERAPEUTICS INC | Healthcare | 2.0% | $46.9m | 3,293,789 | – | new |
| 15 | CRINETICS PHARMACEUTICALS INC | 1.8% | $42.7m | 1,875,209 | 0% | held | |
| 16 | 4XC1 KALVISTA PHARMACEUTICALS INC | 1.8% | $41.2m | 1,441,070 | 0% | held | |
| 17 | KALA PHARMACEUTICALS INC | 1.6% | $37.5m | 4,537,478 | 0% | held | |
| 18 | MNTA MOMENTA PHARMACEUTICALS INC | 1.6% | $37.2m | 2,563,657 | 0% | held | |
| 19 | DICERNA PHARMACEUTICALS INC | 1.6% | $36.0m | 2,456,669 | 0% | held | |
| 20 | EIGER BIOPHARMACEUTICALS INC | 1.5% | $33.8m | 2,415,458 | 0% | held | |
| 21 | DTIL PRECISION BIOSCIENCES INC | 1.4% | $33.1m | 1,842,366 | – | new | |
| 22 | ARVN ARVINAS INC | Healthcare | 1.4% | $31.6m | 2,138,412 | -32% | reduced |
| 23 | MRNA MODERNA INC | Healthcare | 1.3% | $30.8m | 1,513,929 | -0% | held |
| 24 | IOVA IOVANCE BIOTHERAPEUTICS INC | Healthcare | 1.1% | $24.8m | 2,610,510 | -4% | reduced |
| 25 | SLDB SOLID BIOSCIENCES INC | 1.1% | $24.7m | 2,689,444 | 0% | held | |
| 26 | ALEC ALECTOR INC | Healthcare | 0.8% | $18.7m | 1,000,000 | – | new |
| 27 | SHOCKWAVE MED INC | 0.7% | $16.6m | 495,608 | – | new | |
| 28 | SCPHARMACEUTICALS INC | 0.4% | $8.6m | 2,857,143 | 0% | held | |
| 29 | G1 THERAPEUTICS INC | 0.3% | $6.0m | 363,051 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.